CYTOKINETICS, INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.89 USD | -6.78% |
|
-11.01% | -30.66% |
| 05-09 | Oppenheimer Adjusts Cytokinetics Price Target to $106 From $107, Maintains Outperform Rating | MT |
| 05-08 | Cytokinetics Q1 Net Loss Narrows, Revenue Declines | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CYTOKINETICS, INCORPORATED | Bio Therapeutic Drugs | -6.78% | -11.01% | -30.66% | +53.80% | +472.60% | 6.07B |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- CYTK Stock
- Charts Cytokinetics, Incorporated
- Comparison Chart